Real-world outcomes of first-line gemcitabine–platinum plus an immune checkpoint inhibitor and subsequent treatment with matched targeted therapy in biliary tract cancer

ESMO Gastrointestinal Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles